Lead Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Age 18 or older
•Willing to provide informed consent
•ECOG performance status 0-2
•Histologically confirmed non-small cell lung carcinoma
•Locally advanced stage IIIA or IIIB lung carcinoma according to AJCC 7th edition
•Expected lung V20 of 35-60%, as determined at the time of 4D-CT simulation
•Assessment by medical oncologist and radiation oncologist, with adequate hepatic and renal function for administration of cisplatin-based doublet chemotherapy, at the discretion of the medical oncologist

•Serious medical comorbidities or other contraindications to radiotherapy or chemotherapy
•Prior history of lung cancer within 5 years
•Prior thoracic radiation at any time
•Metastatic disease
•in some select cases, patients with a solitary metastasis (i.e. brain metastasis) may receive radical chemoradiotherapy after resection/ablation of their metastatic lesion, as standard practice. In such cases, the patient may be enrolled onto this study at the discretion of the local principle investigator once the metastasis has been treated.
•inability to attend full course of radiotherapy of follow-up visits
•Pregnant or lactating women

Related studies

NCT06364917 · Non Small Cell Lung Cancer

NCT05076760 · Solid Tumor, Advanced Cancer, and more

NCT07169708 · Non Small Cell Lung Cancer NSCLC

NCT06312137 · Non Small Cell Lung Cancer

NCT07563205 · Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, and more

Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer